Sensorimotor deficits affecting voice and swallowing ability can have a devastating impact on the quality of life of people with Parkinson disease (PD). Recent scientific findings in animal models of PD pinpoint targeted exercise therapy as a potential treatment to reduce neurochemical loss and decrease parkinsonian symptoms. Although there may be beneficial effects, targeted exercise therapy is not a standard component of therapy for the cranial sensiromotor deficits seen in PD. In this paper we review the scientific evidence for targeted training for voice and swallowing deficits. The literature search revealed 19 publications that included targeted training for voice and only one publication that included targeted training for swallowing. We summarize 3 main findings: 1) targeted training may be associated with lasting changes in voice behavior, 2) targeted training of sensorimotor actions with anatomical or functional overlap with voice and swallowing may improve voice and swallowing to some degree, but it is unknown whether these effects endure over time, and 3) evidence regarding cranial sensorimotor interventions for Parkinson disease is sparse. We concluded that targeted training for voice and swallow is a promising but understudied intervention for cranial sensorimotor deficits associated with PD and posit that animal models can be useful in designing empirically based studies that further the science on targeted training.
Targeted Physical Exercise and Parkinson DiseaseThe concept of using physical exercise to treat Parkinson disease (PD) is not new. However, interest in exercise on both research and consumer levels has recently escalated because of promising new findings from clinical and animal research (Chen et al.,2005;Fisher et al., 2008;Kurtais et al.,2008;O'Dell et al.,2007;Protas et al.,2005;Toole et al.,2005). In the animal research arena, rodent models of Parkinson disease have been created using neurotoxins such as 6-OHDA (6-hydroxydopamine) and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). These animal models allow preclinical manipulation of neural and behavioral signs of PD, as well as environmental and treatment variables in a systematic